ArticleChinese medicine2019
Metabolomics combined with network pharmacology exploration reveals the modulatory properties of
Article in Chinese medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- 18β-Glycyrrhetinic acid mitigates adverse effects of high-fat diets on liver fibrosis in largemouth bass (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Network Pharmacology-Based Exploration: Non-Targeted Metabolites ofBiologics : targets & therapy · 2026Article
- Phytotherapy in precision medicine era: deciphering herbal modulation of multi-omic biomarkers for cardiovascular metabolic syndrome remodeling.Frontiers in medicine · 2026Article
- Effects and Significance of Dicliptera chinensis Polysaccharide on the Expression of Transforming Growth Factor β1/Connective Tissue Growth Factor Pathway in the Masseter and Head and Neck Skin of Rats With Radiation-Induced Fibrosis.International dental journal · 2025Article
- The total polyphenolic glycoside extract of Lamiophlomis rotata ameliorates hepatic fibrosis through apoptosis by TGF-β/Smad signaling pathway.Chinese medicine · 2023Article
- Optimization of protein removal process ofFood science & nutrition · 2023Article
- Integration strategy of network pharmacology in Traditional Chinese Medicine: a narrative review.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Review
- Review
- Ornithine α-Ketoglutarate Alleviates InflammationFrontiers in nutrition · 2022Article
- Network Pharmacology-Based Prediction and Pharmacological Validation of Effects of Astragali Radix on Acetaminophen-Induced Liver Injury.Frontiers in medicine · 2022Article
- Article
- Mechanism of Huoxue Tongluo Decoction in treatment of erectile dysfunction caused by ischemic stroke based on network pharmacology.Chinese herbal medicines · 2021Article
- UPLC-MS/MS-Based Rat Serum Metabolomics Reveals the Detoxification Mechanism of Psoraleae Fructus during Salt Processing.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Huanglong Antitussive Granule Relieves Acute Asthma Through Regulating Pulmonary Lipid Homeostasis.Frontiers in pharmacology · 2021Article
- Article
- Protective Effect of Ocotillol, the Derivate of Ocotillol-Type Saponins inInternational journal of molecular sciences · 2020Article
- Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism ofFrontiers in pharmacology · 2020Article
- Anemoside B4 protects againstChinese medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMATERIALS AND
methodsUPLC-Q-TOF/MS based metabolomics technique was used to explore the specific metabolites and possible pathways of AR affecting the pathological process of liver fibrosis. Network pharmacology analysis was introduced to explore the key targets of AR regarding the mechanisms on liver fibrosis.
resultsAR significantly reduced the levels of ALT, AST and AKP in serum, and improved pathological characteristics. Metabolomics analysis showed that the therapeutic effect of AR was mainly related to the regulation of nine metabolites, including sphingosine, 6-keto-prostaglandin F1a, LysoPC (O-18:0), 3-dehydrosphinganine, 5,6-epoxy-8,11,14-eicosatrienoic acid, leukotriene C4, taurochenodesoxycholic acid, LysoPC (18:1 (9Z)) and 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine. Pathway analysis indicated that the treatment of AR on liver fibrosis was related to arachidonic acid metabolism, ether lipid metabolism, sphingolipid metabolism, glycerophospholipid metabolism and primary bile acid biosynthesis. Validation of the key targets by network pharmacology analysis of potential metabolic markers showed that AR significantly down-regulated the expression of CYP1B1 and up-regulated the expression of CYP1A2 and PCYT1A.
conclusionMetabolomics combined with network pharmacology was used for the first time to clarify that the treatment of AR on liver fibrosis, which is related to the regulation of arachidonic acid metabolism and ether lipid metabolism by modulating the expression of CYP1A2, CYP1B1 and PCYT1A. And the integrated approach can provide new strategies and ideas for the study of molecular mechanisms of traditional Chinese medicines in the treatment of liver fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.